Home › Jazz Pharmaceuticals Plc And Concert Pharmaceuticals Announce Worldwide Licensing Agreement To Develop And Commercialize Deuterium-Modified Sodium Oxybate
 

Keywords :   


Jazz Pharmaceuticals Plc And Concert Pharmaceuticals Announce Worldwide Licensing Agreement To Develop And Commercialize Deuterium-Modified Sodium Oxybate

2013-02-26 17:15:00| drugdiscoveryonline News Articles

Jazz Pharmaceuticals plc and Concert Pharmaceuticals, Inc. recently announced an exclusive license agreement that provides Jazz Pharmaceuticals worldwide rights to develop and commercialize Concert’s deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323

Tags: agreement develop worldwide jazz

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
24.09Tropical Storm Helene Forecast Discussion Number 6
24.09Tropical Storm Helene Wind Speed Probabilities Number 6
24.09Tropical Storm Helene Public Advisory Number 6
24.09Summary for Tropical Storm Helene (AT4/AL092024)
24.09Tropical Storm Helene Forecast Advisory Number 6
24.09US accuses Visa of debit card monopoly
24.09China probes Calvin Klein over Xinjiang cotton
24.09EPA Names ACI as 2024 Safer Choice Partner of the Year
More »